Abstract
Background: The majority of commensal gastrointestinal bacteria used as probiotics are highly adapted to the specialised environment of the large bowel. However, unlike pathogenic bacteria; they are often inadequately equipped to endure the physicochemical stresses of gastrointestinal (GI) delivery in the host. Herein we outline a patho-biotechnology strategy to improve gastric delivery and host adaptation of a probiotic strainBifidobacterium breveUCC2003 and the generally regarded as safe (GRAS) organismLactococcus lactisNZ9000.Results: In vitrobile tolerance of both strains was significantly enhanced (P< 0.001), following heterologous expression of theListeria monocytogenesbile resistance mechanism BilE. Strains harbouringbilEwere also recovered at significantly higher levels (P< 0.001), than control strains from the faeces and intestines of mice (n= 5), following oral inoculation. Furthermore, aB. brevestrain expressingbilEdemonstrated increased efficacy relative to the wild-type strain in reducing oralL. monocytogenesinfection in mice.Conclusion: Collectively the data indicates that bile tolerance can be enhanced inBifidobacteriumandLactococcusspecies through rational genetic manipulation and that this can significantly improve delivery to and colonisation of the GI tract.

This publication has 35 references indexed in Scilit: